MX342444B - Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg). - Google Patents

Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).

Info

Publication number
MX342444B
MX342444B MX2013002554A MX2013002554A MX342444B MX 342444 B MX342444 B MX 342444B MX 2013002554 A MX2013002554 A MX 2013002554A MX 2013002554 A MX2013002554 A MX 2013002554A MX 342444 B MX342444 B MX 342444B
Authority
MX
Mexico
Prior art keywords
erythropoietin
residue
ethylene glycol
cation exchange
pegylated erythropoietin
Prior art date
Application number
MX2013002554A
Other languages
English (en)
Other versions
MX2013002554A (es
Inventor
Kuhne Wolfgang
Falkenstein Roberto
Koehnlein Wolfgang
Schurig Hartmut (Fallecido) Representado Por Su Heredera Legal Sibylle Schurig
Original Assignee
F Hoffmann-La Roche Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann-La Roche Ag * filed Critical F Hoffmann-La Roche Ag *
Publication of MX2013002554A publication Critical patent/MX2013002554A/es
Publication of MX342444B publication Critical patent/MX342444B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para la purificación de una proteína que comprende eritropoyetina y un residuo individual de poli(etilenglicol) de subproductos de reacción o un material de partida sin reaccionar por medio de un método de cromatografía de intercambio catiónico. Se ha descubierto que al emplear un material de cromatografía de intercambio catiónico SP Sephacryl S 500 HRMR acondicionado a una conductividad de 21 mS/cm y una elución de gradiente lineal, una proteína de fusión de eritropoyetina y un residuo individual de poli(etilenglicol) se pueden obtener en un paso individual con alta pureza y alto rendimiento. Figura 1.
MX2013002554A 2010-09-14 2011-09-13 Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg). MX342444B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10176616 2010-09-14
PCT/EP2011/065888 WO2012035037A1 (en) 2010-09-14 2011-09-13 Method for purifying pegylated erythropoietin

Publications (2)

Publication Number Publication Date
MX2013002554A MX2013002554A (es) 2013-05-28
MX342444B true MX342444B (es) 2016-09-29

Family

ID=43385653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002554A MX342444B (es) 2010-09-14 2011-09-13 Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).

Country Status (15)

Country Link
US (4) US20120197007A1 (es)
EP (1) EP2616101B1 (es)
JP (1) JP5735650B2 (es)
KR (1) KR101578586B1 (es)
CN (1) CN103118708B (es)
BR (1) BR112013005890B1 (es)
CA (1) CA2808748C (es)
DK (1) DK2616101T3 (es)
ES (1) ES2500048T3 (es)
HK (1) HK1181661A1 (es)
MX (1) MX342444B (es)
PL (1) PL2616101T3 (es)
RU (1) RU2566267C2 (es)
SI (1) SI2616101T1 (es)
WO (1) WO2012035037A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
DE102016210647B3 (de) 2016-06-15 2017-09-14 Schaeffler Technologies AG & Co. KG Keilkupplung-Synchronisation
EP3484911B1 (en) 2016-07-15 2020-11-04 H. Hoffnabb-La Roche Ag Method for purifying pegylated erythropoietin
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
SG11202005990RA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
CN111801120A (zh) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
PL3731873T3 (pl) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE69032809T2 (de) 1989-11-06 1999-07-08 Cell Genesys, Inc., Foster City, Calif. Herstellung von Proteinen mittels homologer Rekombination
DE69034135T3 (de) 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
DE4118912C1 (es) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0651761B1 (en) 1992-07-13 2002-10-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CZ300546B6 (cs) 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003265994B2 (en) * 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CA2736141C (en) 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
MX2011008963A (es) 2009-03-05 2012-02-01 Ascendis Pharma As Profarmacos portadores de interferon alfa.

Also Published As

Publication number Publication date
HK1181661A1 (en) 2013-11-15
KR101578586B1 (ko) 2015-12-17
CN103118708A (zh) 2013-05-22
BR112013005890B1 (pt) 2022-02-08
WO2012035037A1 (en) 2012-03-22
RU2566267C2 (ru) 2015-10-20
US20120197007A1 (en) 2012-08-02
JP5735650B2 (ja) 2015-06-17
CA2808748C (en) 2018-09-11
BR112013005890A2 (pt) 2020-04-14
DK2616101T3 (da) 2014-08-04
KR20130073964A (ko) 2013-07-03
US20210094993A1 (en) 2021-04-01
ES2500048T3 (es) 2014-09-29
US20170008941A1 (en) 2017-01-12
JP2013537208A (ja) 2013-09-30
SI2616101T1 (sl) 2014-10-30
CA2808748A1 (en) 2012-03-22
MX2013002554A (es) 2013-05-28
CN103118708B (zh) 2015-08-26
US20140163207A1 (en) 2014-06-12
EP2616101B1 (en) 2014-07-09
PL2616101T3 (pl) 2015-01-30
EP2616101A1 (en) 2013-07-24
RU2013113724A (ru) 2014-10-20
US10273277B2 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2013002554A (es) Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).
IL227691A0 (en) Creation and purification of 29 – il
MY186089A (en) Chromatographic processes and purified compounds thereof
JO3796B1 (ar) ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t
RU2014148136A (ru) Композиции т-клеток с недостаточностью рецепторов т-клеток
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
MY156181A (en) Method and system for producing high-purity hydrogen chloride
MX2013001447A (es) Metodo de produccion y purificacion de una sialiltransferasa soluble activa.
MX2013009774A (es) Anticuerpo de fc especifico para fcyriib.
CY1116963T1 (el) Μεθοδος για καθαρισμο ανασυνδυασμενης fsh
WO2014178078A3 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
WO2012024368A3 (en) Method of synthesis of substituted hexitols such as dianhydrogalactitol
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
MX342235B (es) Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
PH12015502408B1 (en) Purification of iduronate-2-sulfatase
IN2013CN00459A (es)
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
IN2014DN02166A (es)
EP1967242A4 (en) PROCESS FOR THE INDUSTRIAL PRODUCTION OF DIALKYL CARBONATE AND DIOL
CN103113227B (zh) 3-甲氧基丙烯酸甲酯的制备方法
MY160954A (en) Agomelatine intermediates and preparation method thereof
MX2014001861A (es) Polipeptidos con actividad proteasa.
MD20160071A2 (ro) Procedeu nou de sinteză a agomelatinei
NZ707753A (en) Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
FR2985998B1 (fr) Procede de production d'acrylate de 2-octyle par transesterification

Legal Events

Date Code Title Description
FG Grant or registration